Deucravacitinib
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis[1][2].
Product Specifications
CAS Number
1609392-27-9
Product Name Alternative
BMS-986165
UNSPSC
12352005
Hazard Statement
H361, H372
Target
IFNAR; Interleukin Related; Isotope-Labeled Compounds; JAK
Type
Isotope-Labeled Compounds
Related Pathways
Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Purity
99.93
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]
Molecular Formula
C20H19D3N8O3
Molecular Weight
425.46
Precautions
H361, H372
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
Launched
Isoform
IL-12; IL-23; JAK1; Tyk2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FAM110A (NM_001042353) Human Over-expression Lysate
